On February 14, Humanwell Healthcare (Group) Co.Ltd(600079) announced that Yichang humanwell Pharmaceutical Co., Ltd., a holding subsidiary, had received the drug registration certificate of memantine hydrochloride sustained-release capsule approved and issued by the State Drug Administration.
Memantine hydrochloride sustained release capsule is used to treat moderate to severe Alzheimer’s dementia. Yichang humanwell’s memantine hydrochloride sustained-release capsule was approved by FDA in April 2021, and its registration application was submitted to the State Drug Administration in April 2020 and accepted. Up to now, the cumulative R & D investment of the project is about 20 million yuan.
According to the data of Intranet, in 2020, the sales of all memantine dosage forms in the three terminal public hospitals of cities, counties and towns in China were about 600 million yuan. The main manufacturers included H. lundbeck A / s, Zhuhai United Laboratories Co., Ltd.
